Transcript Highlights:

• Is there any movement by the FDA... and thank you all for coming today.
• /c><00:12:19.920> movement<00:12:20.399> by<00:12:20.639> the<00:12:20.880> FDA
• Is there any movement by the FDA to approve this so that it would be covered by insurance plans?

Keywords: 958, all

Summary: The committee heard House Bill 369, which would add post-traumatic stress disorder to an existing 2018 hyperbaric oxygen therapy-related law for veterans. Representative Scott Sharp and HBOT for KY Vets representatives testified that PTSD and traumatic brain injury often overlap, that veterans are frequently misdiagnosed, and that hyperbaric oxygen therapy has shown benefits in clinical trials and in Kentucky’s own funded program. Members asked whether the bill would require insurance coverage; the sponsors said it would not, and noted they are seeking broader approval through medical and congressional channels. The committee voted favorably on HB 369, with members expressing support based on personal experience and the needs of veterans and their families. The committee then considered House Bill 419, for which a committee substitute was adopted before testimony. Representative Suzanne Miles and Kentucky Fire Commission/KCTCS representatives explained that the bill would expand the fire commission board from 14 to 18 members, clarify that KCTCS’s 5% administrative fee applies collectively to all funds rather than separately to each fund, and allow excess funds to help cover out-of-pocket cancer screening costs for volunteer and paid firefighters. A question about board staggering was answered by explaining that staggered terms were originally used to avoid all terms ending at once and were expected to continue. The committee passed HB 419 with favorable expression. Later, USA Cares presented an update on how it has used prior state funding. The organization described its grant-based assistance for veterans and military families facing housing, vehicle, and utility crises, as well as career transition and housing-related support programs. Testimony emphasized that the aid helps prevent homelessness and reduce suicide risk, and the group reported it had used nearly all of the $2 million awarded in the last budget cycle to assist 364 families and more than 500 dependents. No vote was taken on the USA Cares presentation.

Transcript Highlights:

• the bill does is let physicians treat patients with stem cell therapies that are not approved by the FDA
• Additionally, the FDA regulates...
• The bill concerns only stem cell therapies not approved by the FDA. Thank you for the question.

Bills: HB135, HCR64, SCR3, SCR30, SB500, SB739, SB816, SB898, SB1283, SB1351, SB1423, SB1531, SB1540, SB1666, SB1721, SB1886, SB1931, SB2001, SB2075, SB2154, SB2173, SB2217, SB2284, SB2375, SB2383, SB2386, SB2398, SB2448, SB2476, SB2540, SB2580, SB2589, SB2693, SB2707, SB2776, SB2786, SB2801, SB2864, SB2927, SJR84, SCR30, SB243, SB324, SB393, SB457, SB511, SB529, SB547, SB636, SB646, SB659, SB715, SB731, SB735, SB800, SB801, SB904, SB1065, SB1141, SB1181, SB1224, SB1241, SB1242, SB1250, SB1266, SB1285, SB1359, SB1434, SB1442, SB1467, SB1502, SB1524, SB1528, SB1551, SB1585, SB1640, SB1754, SB1757, SB1777, SB1844, SB1863, SB1972, SB2007, SB2035, SB2046, SB2055, SB2069, SB2082, SB2119, SB2139, SB2154, SB2200, SB2201, SB2269, SB2310, SB2330, SB2357, SB2366, SB2401, SB2422, SB2514, SB2530, SB2533, SB2543, SB2544, SB2550, SB2568, SB2589, SB2660, SB2693, SB2695, SB2707, SB2717, SB2721, SB2742, SB2753, SB2807, SB2846, SB2891, SB2925, SB2938, SJR3, SJR18, SB5, SB326, SB767, SB769, SB783, SB914, SB963, SB1035, SB1197, SB1271, SB1415, SB1437, SB1619, SB1637, SB1786, SB1806, SB494, SB530, SB2312, SB1, SB260, HB135, HB 1109, HB1392, HB22, HCR64, SJR36, SJR50, SJR63, SJR84, SJR59, SCR12, SCR39, SCR48, SCR19, SCR30, SCR3, SB2023, SB62, SB666, SB847, SB284, SB854, SB1073, SB810, SB1505, SB583, SB1502, SB507, SB1434, SB1376, SB1585, SB1772, SB2016, SB1163, SB1122, SB731, SB397, SB508, SB1436, SB287, SB261, SB1882, SB393, SB1791, SB209, SB2429, SB1999, SB511, SB2309, SB510, SB1085, SB1975, SB2717, SB1262, SB1524, SB636, SB2056, SB884, SB517, SB1200, SB1845, SB1863, SB2681, SB2200, SB2199, SB1757, SB2458, SB2201, SB801, SB2533, SB3014, SB3013, SB758, SB1721, SB1013, SB2797, SB2383, SB2119, SB2448, SB1777, SB1283, SB2076, SB2786, SB2876, SB2284, SB1540, SB2929, SB2540, SB2595, SB2217, SB715, SB500, SB1640, SB2001, SB2514, SB2753, SB2398, SB1241, SB2927, SB2173, SB2538, SB898, SB1449, SB2529, SB2846, SB2476, SB986, SB1181, SB2075, SB2154, SB2864, SB1359, SB2386, SB2550, SB1351, SB1423, SB1931, SB2245, SB2589, SB2707, SB410, SB2776, SB2580, SB1886, SB1234, SB739, SB456, SB1666, SB2801, SB2055, SB1012, SB2926, SB2138, SB1242, SB2615, SB2310, SB1224, SB2972, SB2841, SB3016, SB2139, SB1856, SB2035, SB1528, SB1141, SB2401, SB2530, SB2375, SB547, SB1266, SB1373, SB1467, SB2069, SB2269, SB2480, SB672, SB904, SB2695, SB2891, SB2422, SB2543, SB1854, SB317, SB2539, SB2532, SB2925, SB1250, SB2082, SB2203, SB457, SB2357, SB2721, SB243, SB1285, SB2568, SB1959, SB1442, SB1454, SB2520, SB2541, SB1708, SB1237, SB1844, SB1586, SB1551, SB3039, SB2819, SB66, SB629, SB1015, SB2342, SB2903, SB2933, SB1965, SB2477, SB3029, SB2605, SB2419, SB1957, SB375, SB250, SB777, SB628, SB2523, SB2367, SB2703, SB2608, SB2778, SB3044, SB2965, SB2521, SB865, HB2525, HB3093, SB1032, SB2165, SB2501, SB2675, SB2452, SB2835, SJR84, SB457, SB547, SB904, SB1467, SB1757, SB1777, SB2055, SB2069, SB2139, SB2401, SB2530, SB2543, SB2695, SR349, SR367, SR468, SB3064, SB3065, HJR7, HB 119, HB 130, HB163, HB166, HB201, HB272, HB331, HB380, HB654, HB694, HB718, HB865, HB 1266, HB1397, HB1500, HB1552, HB1576, HB1583, HB1584, HB1760, HB1894, HB1965, HB2018, HB2029, HB2286, HB2340, HB2427, HB2455, HB2467, HB2508, HB2523, HB2730, HB2756, HB2791, HB2970, HB3016, HB3096, HB3248, HB3255, HB3336, HB3623, HB3698, HB3699, HB3803, HB3804, HB3805, HB3806, HB4129, HB4187, HB4236, HB4238, HB4643, HB4738, HB4739, HB5333, SCR3, SCR30, SB500, SB739, SB898, SB1283, SB1351, SB1423, SB1540, SB1666, SB1721, SB1886, SB1931, SB2001, SB2075, SB2154, SB2173, SB2217, SB2375, SB2383, SB2386, SB2398, SB2448, SB2476, SB2540, SB2580, SB2589, SB2707, SB2776, SB2786, SB2801, SB2864, SB2927, HB135, HCR64, SB2284, SB3064, SB3065, HJR7, HB 119, HB 130, HB163, HB166, HB201, HB272, HB331, HB380, HB654, HB694, HB718, HB865, HB 1266, HB1397, HB1500, HB1552, HB1576, HB1583, HB1584, HB1760, HB1894, HB1965, HB2018, HB2029, HB2286, HB2340, HB2427, HB2455, HB2467, HB2508, HB2523, HB2730, HB2756, HB2791, HB2970, HB3016, HB3096, HB3248, HB3255, HB3336, HB3623, HB3698, HB3699, HB3803, HB3804, HB3805, HB3806, HB4129, HB4187, HB4236, HB4238, HB4643, HB4738, HB4739, HB5333

Keywords: sales tax exemption, exotic animals, game animals, agriculture, livestock, gifted education, education support, student achievement, academic excellence, Texas education, cowboy culture, Bandera, cultural heritage, historical significance, Texas identity, Birding Capital, Matagorda County, wildlife, conservation, Texas Legislature

Transcript Highlights:

• /c><02:04:08.560> oversight<02:04:09.040> for<02:04:09.199> these there are no FDA
• It is not approved by the FDA. Dr.
• It is not approved by the<02:09:54.639> FDA.<02:09:55.440> Dr.
• Marty Mccuri, who I just the FDA. Dr.
• Um, both the FDA and the Drug Enforcement Agency have issued public cautions on it, and we were given

Keywords: 958, all

Summary: The committee first approved the minutes and then approved an agency amendment to a health and family services regulation. The amendment reversed a prior change so that neonatal ICU beds would remain subject to regular review rather than nonsubstantive review. The remaining administrative regulations were then reviewed without objection. The main presentation was from State Auditor Allison Ball on a report finding $836 million in concurrent Medicaid capitation payments from 2019 through 2022, involving individuals enrolled in Kentucky and at least one other state. Ball said Kentucky relied on the PARIS system, which has limitations because it is updated quarterly and depends on voluntary state participation, while a better federal data source, T-MSIS, was not fully available to the state. She said the audit found weak internal controls, siloed processes, outdated guidance, and a low-priority attitude toward residency checks, all of which contributed to missed alerts and improper payments. She also said the report identified additional problems, including payments made after beneficiaries died and cases involving multiple states paying for the same person. Ball recommended better access to federal data, stronger MCO contract provisions, and more active oversight by the Department for Medicaid Services and managed care organizations. She said the contracts reviewed did not provide a clear way to recoup the improper payments, though she and her counsel suggested possible equitable legal theories might be explored. Members expressed concern about the scale of the waste and the lack of contract enforcement, and asked whether any money could be recovered. Ball said the audit did not identify a clear contractual path to recoup the funds.

Transcript Highlights:

• rating scales, et cetera, opioids for the last 30 years, like I said, have been the only approved or FDA-approved
• But in that space, opioids for the last 30 years, like I said, have been the only approved or FDA-approved
• Khan, so I know this has only been FDA-approved for, I mean, just shy of 18 months probably now.
• So I know this has only been FDA-approved for, I mean, just shy of 18 months probably now.

Summary: The committee first approved the minutes and then heard a detailed annual presentation from Dr. Thomas Arnold, chair of the Maternal Mortality Review Committee, on maternal mortality trends and review findings. He explained the committee’s structure, the de-identified review process, and the distinction between pregnancy-associated and pregnancy-related deaths. He said national maternal mortality has declined from its 2021 peak, but mental health conditions, substance use, overdose, suicide, cardiovascular disease, hemorrhage, infection, and embolism remain major causes. He emphasized that many deaths are preventable, with especially high rates among non-Hispanic Black women and in the American Indian/Alaska Native population, and noted that a large share of deaths occur after 42 days postpartum. Committee members asked about suicide, domestic abuse, pregnancy testing in unexplained deaths, and the role of home births and midwife training. Dr. Arnold said the committee is adding a caseworker, exploring post-mortem pregnancy testing in suspicious cases, and working with coroners and forensic officials; he also said home births and untrained midwifery pose safety concerns and that better public education and facility-based care are important. The committee then heard from State Fire Marshal Dr. Matt Clark on cigarette ignition propensity standards and fire prevention. He recommended updating North Dakota’s cigarette ignition legislation to the current national standard and also considering legislation requiring fast-breakaway oxygen tubing, citing fatal fires involving smoking around home oxygen. He explained that his office verifies manufacturer testing and maintains certification for cigarettes sold in the state, but does not itself conduct the testing. Members asked about implementation, cost, and whether the standards apply in tribal communities; Clark said he would follow up with cost information and additional details, and that he had not seen evidence of a major issue on tribal lands but would look further. Christine Greff of the Department of Health and Human Services presented the North Dakota Stroke System of Care report. She described the statewide network of two comprehensive stroke centers, four primary stroke centers, and 30 acute stroke-ready hospitals, along with the stroke registry and quality-improvement efforts. She reported that most strokes are ischemic, that the median stroke patient age is 71.5, and that common risk factors include hypertension, dyslipidemia, obesity, and diabetes. She highlighted improvements in door-to-CT, thrombolytic treatment times, dysphagia screening, EMS pre-notification, and interfacility transfer performance, and said new priorities include hemorrhagic stroke quality measures and standardized EMS stroke screening tools. Members asked about the VA hospital’s participation, and Greff said she would pursue outreach. After a break, the committee heard testimony from Taha Khan of Vertex Pharmaceuticals as part of the prior authorization study, focused on non-opioid pain treatment. He argued that prior authorization can delay access to acute pain treatment and may push patients toward opioids, especially in the critical 24- to 72-hour post-discharge window. He cited data showing that even short opioid exposure can increase the risk of long-term use and said prior authorization is often a barrier for physicians and patients. Khan recommended open access with a quantity limit rather than prior authorization, suggesting a 14-day limit supported by the product’s data and an episode-of-care approach. Members asked about dental use, payer discussions, and cost; he said the product’s wholesale acquisition cost is about $16.10 per tablet, with patient assistance available, and that he would follow up on payer and comparison-cost questions.

Transcript Highlights:

• We do not have FDA-approved medications for stimulant use disorder.
• We do not have FDA-approved medications for stimulant use disorder yet, though there is ongoing research
• I think while opioid use disorder has multiple FDA-approved treatments, we're certainly seeing a rise
• So they don't have any medications that are FDA approved.

Summary: The task force meeting opened with new leadership announcements, including Senator Nick Schroer thanking outgoing chair Representative John Black and naming Representative Del Taylor as vice chair. After some initial technical difficulties with audio and Zoom, members reviewed the task force’s statutory charge under Missouri law: to hold hearings on substance use, explore solutions, draft or modify legislation, and produce recommendations for prevention and treatment. The chair said the goal for this year is to develop concrete legislative ideas for the next session, with hearings focused first on field experts and later on alternative therapies and the Department of Mental Health. Dr. Rachel Winograd gave the first major presentation, describing Missouri’s overdose crisis as increasingly complex and driven primarily by fentanyl, now compounded by xylazine and metatomidine. She said overdose deaths have declined for a third straight year, with preliminary 2025 data around 1,200 deaths, and attributed the decline to a smaller fentanyl supply, wider naloxone availability, and fewer young people entering use. Her main recommendations were to focus on reducing harm rather than trying to eliminate drug use, expand evidence-based medications for opioid use disorder—especially methadone and buprenorphine—improve access to naloxone, and loosen methadone regulations, including take-home doses, the federal 72-hour rule, and broader methadone units. She also emphasized that peer support, housing, transportation, and other practical supports matter, and noted that naloxone can still reverse fentanyl overdoses even when tranquilizers are present. Dr. Heidi Miller, the state medical director, followed with two recommendations: integrate substance use disorder care into whole-person health care and follow the science when considering substance-related legislation. She argued that primary care, maternal health, workforce training, EMS, public health, and methadone access should all be part of a coordinated model, and said reimbursement should support teams rather than isolated providers. She also urged stronger enforcement of parity between behavioral health/SUD and physical health coverage, and highlighted tobacco and alcohol as major, under-addressed causes of death in Missouri. Dr. Doug Burgess then reinforced the need for a coordinated continuum of care, comparing substance use treatment to the seamless system used for heart attacks, and said patients should have standardized assessment, discharge planning from day one, transition coordinators, peer recovery coaches, and better information-sharing between levels of care. Members asked questions about relapse, treatment court, EMS referral barriers, reimbursement, and whether buprenorphine can be started in the field; no votes were taken, and the meeting ended with plans to continue hearing testimony and use it to shape future policy recommendations.

Transcript Highlights:

• You have to get FDA approval and, once you're approved, then you have to go through CMS to get reimbursement
• You<00:46:28.880> have<00:46:28.960> to<00:46:29.040> get<00:46:29.200> FDA
• You have to get FDA approval and viable.
• You have to get FDA approval and once<00:46:30.640> you're<00:46:30.800> approved<00:46

Keywords: 928, house, all

Summary: The committee met to review tax expenditures, elect a chair and clerk, and hear updates on two credits due for periodic review: the career and technical education (CTE) center tax credit and the research and development (R&D) tax credit. Members first organized the meeting, then heard from Jennifer Ramsey of DRA, who explained the purpose of the tax expenditure review process and summarized the CTE and R&D credits. She said the CTE credit allows donations to CTE centers for a credit against business profits tax, is capped at 25% of a taxpayer’s liability, has a $500,000 aggregate limit, and was extended in SB 98 to fiscal year 2031. She also noted DRA could not provide detailed financial data because of statistical disclosure limits when too few taxpayers claim the credit. Committee members pressed for more historical and aggregate information, arguing they needed numbers to judge whether the credit is effective and worth continuing. The committee then heard from Chrissy Vanderhook of the Department of Education on the CTE credit. She described New Hampshire’s CTE system as serving 26 secondary centers and seven post-secondary centers, with industry partners providing internships, work-based learning, equipment, employee time, and other in-kind support that can qualify for the credit. She said the department reports annually to legislative leaders and that fiscal year 2025 credit activity was down about 48% from FY24, partly due to staffing changes and outreach issues. Members asked whether the program extends to community college-level programs, and she said it can, though she was not sure how broadly it is used that way. The committee also discussed a new Granite Patron of the Arts credit, which DRA said went into effect July 1 and is included in the tax expenditure report even though it is not yet listed in the statute. For the R&D credit, Ramsey explained that it offsets business profits tax and can carry forward to business enterprise tax, is based on incremental research spending, and currently has a $7 million annual aggregate cap. She said the cap has not yet been reached but could require proration as early as fiscal year 2026 if not increased. She noted there were 271 taxpayers claiming the credit in fiscal 2024 and that a proposal last session to raise the cap to $10 million and increase the per-company limit did not advance. Mark Liberty of BEA said the credit is an important recruitment and retention tool, especially for life sciences, aerospace, defense, and advanced manufacturing, but acknowledged BEA does not track direct revenue return. Andrea Hchvaria of New Hampshire Life Sciences argued the R&D credit is critical for startups and cited growth in applicants from 71 in 2008 to 248 in 2024, with qualified wages rising substantially over that period. Committee members repeatedly asked for more objective economic-impact data, but DRA said it only tracks who claimed the credit and the amount claimed, not broader business outcomes.

Transcript Highlights:

• These are all FDA regulated.
• These are all FDA regulated.
• I think these are all FDA regulated.
• FDA may and um it's in the box there.
• If the FDA requires disclosure for If the FDA requires disclosure for clinical<05:05:29.440> research

Keywords: 1189, house, all

Transcript Highlights:

• Dana-Farber's clinical regimens are FDA-approved and NCCN, which is a Medicare compendia, supported.
• Dana-Farber's oncologist prescribed an FDA-approved drug as a second-line therapy for metastatic disease

Keywords: 995, all

Summary: The committee held a hearing on several health care access and insurance-related bills, with most testimony focused on H.1136 to improve the prior authorization process. The Massachusetts Medical Society, Massachusetts Health and Hospital Association, Health Care for All, the Leukemia & Lymphoma Society, physicians, and hospital representatives all supported the bill, arguing that prior authorization delays care, increases administrative burden, contributes to clinician burnout, and can worsen patient outcomes. Witnesses described examples involving delayed cancer treatment, diabetes care, COPD medication, shingles pain treatment, and hospital discharge delays. They said the bill would preserve prior authorization but add guardrails such as longer validity periods, continuity-of-care protections, faster responses for urgent care, clearer lists of services requiring authorization, and more transparency and standardization. The committee also heard testimony on H.1142/S.783 regarding equitable reimbursement for certified registered nurse anesthetists (CRNAs), with Senator Lovely and CRNA advocates supporting parity with physician anesthesiologists. They said CRNAs provide the same services at the same standard of care, but private insurers sometimes reimburse them at lower rates than physicians, which they argued is inconsistent with federal and state policy and harms access. Senator Keenan testified in support of a bill addressing claim denials and appeals, saying insurers should provide clearer explanations, time to resubmit claims, and timely appeal responses. Dr. Lorraine Schratz supported H.1126 to align state patient disclosure requirements with federal No Surprises Act rules, and Dr. Michael Trimbley supported H.1120 to recognize direct primary care as not being insurance and to encourage primary care participation. The committee also heard testimony on H.1140/S.801 to remove barriers to patient care by updating insurance statutes to reflect nurse practitioners’ full practice authority, and on H.1168/S.A.18 to eliminate the PCP referral requirement for specialty gynecological care. Witnesses on those bills described delays and denials affecting autism diagnosis, nutrition coverage, and endometriosis care, and said the proposals would reduce unnecessary barriers and improve timely access. After testimony and a few member questions, the chair closed the hearing; no votes were taken during the session.

Transcript Highlights:

• medical doctor writing an order for the patient, and it is a practice outlined and approved by the FDA
• Sure, so blood thinners are licensed by the FDA.

Transcript Highlights:

• that finished ceramic products, like a mug or a plate, are subjected to food safety testing through FDA
• assorted products have shown low levels of extractable lead and cadmium and are in compliance with FDA

Transcript Highlights:

• >> IF IT HAD TO DO WITH MILITARY DONE THE FLORIDA FDA WOULD BE INVOLVED IN VETERANS AFFAIRS OF THE INVOLVED
• SIGNIFICANT, OF HISTORICAL SIGNIFICANCE THAT OF BEEN UP FOR 25 YEARS, IF IT WAS MILITARY WOULD GO TO FDA

Keywords: 999, senate, all

Transcript Highlights:

• /c><01:24:52.400> approved<01:24:52.800> by<01:24:53.440> the<01:24:54.719> FDA
• <01:24:55.679> So, system that is approved by the FDA.
• So, system that is approved by the FDA.
• stem cells are being offered, but they're being offered in a very limited approach right now under FDA
• limited approach right now under FDA limited approach right now under FDA regulation.<01:40:04.960

Keywords: 916, all

Transcript Highlights:

• This takes away the right for adults to consume FDA-authorized products.
• <00:48:32.680> that have been approved even by the FDA that have been approved even by the
• FDA that are<00:48:32.960> Geared<00:48:33.280> for<00:48:33.599> adults<00:48:
• takes away the right for adults to this takes away the right for adults to consume<00:48:40.680> FDA
• authorized products we all consume FDA authorized products we all agree<00:48:44.079> that<00

Keywords: 910, house, all

Summary: The committee heard testimony on several bills. HB 655 would limit collection of unpaid motor vehicle taxes, fees, and penalties to the most recent five consecutive years of delinquency. The Department of Transportation opposed the bill, saying it could significantly affect state and county revenues and that the fiscal impact was hard to estimate. The Tax Foundation noted the bill would shorten the existing collection period, while an individual testifier supported it as a narrow measure that would help owners of old or inherited vehicles. In questioning, the department said it could not quantify the cost but suggested it would prefer case-by-case flexibility rather than a fixed five-year limit. HB 697 would authorize Department of Transportation and Department of Law Enforcement personnel to inspect and certify evidence from automated speed enforcement systems and would appropriate funds for the program. The Department of Transportation supported the measure, citing the workload created by the red-light camera pilot and the need to assist police and prosecutors. The Department of the Attorney General supported the concept but recommended technical amendments so the verification language would apply consistently across the chapter and allow the appropriate reviewing entity to act. The committee also heard support from the AAHU Metropolitan Planning Organization and opposition from three individuals. HB 711 would require defendants convicted of causing the death of a parent or legal guardian of a minor child while driving under the influence to provide financial support to the surviving child. The Office of the Public Defender opposed the bill, arguing that criminal restitution must be tied to verified losses and that this type of long-term support is better handled in civil court, where trusts, conservatorships, and insurance claims can be addressed. The Department of Transportation supported the bill as a deterrent to impaired driving, and police, prosecutors, and an injury prevention group also submitted support. Members questioned whether the measure was better suited to civil litigation, and the public defender agreed that the civil system was the proper venue. HB 108 would allow direct shipment of beer and distilled spirits by certain licensees and require county liquor commissions to adopt rules. The Attorney General raised constitutional concerns, saying the bill’s different treatment of out-of-state manufacturers could violate the dormant Commerce Clause and recommended revisions. Brewers and distillers testified in support, saying the bill would put beer and spirits on a similar footing with wine direct shipment, help small producers reach consumers, and support the local economy without increasing underage access. They also said the bill should be amended to address grandfathering language. No final votes or committee actions were taken in the portion of the hearing provided.

Transcript Highlights:

• I won't dispute that Ivermectin is FDA approved for certain uses, but it is not safe or effective as

Bills: HB25

Keywords: ivermectin, pharmacist authority, prescription-free, healthcare regulation, patient access, 1185, senate, all

Transcript Highlights:

• Ivermectin is FDA approved for certain uses, but it is not safe or effective as a cure-all for COVID,

Bills: HB25

Keywords: ivermectin, pharmacist authority, prescription-free, healthcare regulation, patient access

Transcript Highlights:

• Those hormones wouldn't be covered by insurance as they were not FDA approved.
• Last March, I finally started hormone therapy, FDA-approved hormone therapy, after finding a telehealth
• Those hormones wouldn't be covered by insurance as they were not FDA approved.
• Last March, I finally started hormone therapy, FDA-approved hormone therapy, after finding a telehealth
• The last thing I just want to say is if you go onto the FDA website right now and you look at the mifepristone

Keywords: 995, all

Summary: The committee opened by explaining hearing procedures and time limits, then heard testimony on House 2499, a bill to create a public awareness campaign on menopause and related midlife health issues. Supporters, including a nurse, the Massachusetts Commission on the Status of Women, and other advocates, said menopause is widely misunderstood by patients and providers, leading to delayed care, unnecessary suffering, workplace impacts, and inequities in women’s health. Several speakers shared personal experiences with symptoms being dismissed or misdiagnosed and urged the committee to advance the bill. The committee then took testimony on a package of endometriosis bills, including House 2527 and Senate 1564, calling for a task force and broader awareness efforts. Patients, a physician, and advocates described long diagnostic delays, severe pain, infertility, medical gaslighting, and limited access to specialists and effective treatment. They argued for more research, provider education, and a coordinated state strategy, and several asked for favorable reports. The chair also noted the hearing was running behind and extended time to allow more testimony. Later, the committee heard Senate 1579, which would eliminate parental consent and judicial bypass requirements for abortion access for minors under 16. Planned Parenthood representatives, physicians, legal advocates, and students argued the current law creates unnecessary delays and harms vulnerable youth, especially those in unsafe homes or foster care, while supporters said minors can already consent to other reproductive health care. A pro-life witness opposed the bill and emphasized parental involvement and support services. The committee also heard House 2403 and Senate 1560, which would create a Human Service Transportation Consumer Advisory Board; disability advocates and riders described past safety problems and current service gaps, and supported the board as a low-cost way to improve accountability, rider input, and reliability. No votes or final actions were taken in the excerpt.

Keywords: 928, house, all

Summary: The Environment and Agriculture Committee held an introductory orientation for members, many of whom were new or newly assigned to the committee. Leadership emphasized that the committee is intended to operate in a nonpartisan, collaborative way, and members introduced themselves and described their backgrounds in farming, gardening, food service, environmental work, water and waste issues, veterinary work, and related fields. Several members noted personal ties to homesteading, livestock, orcharding, food security, landfill concerns, and animal welfare, while others said they were eager to learn the committee’s work. The chair then reviewed committee procedures and expectations. Members were told the committee would generally meet on Tuesdays, with hearings starting around 10 a.m. and often running until about 4:30 p.m., and that absences, substitutes for executive sessions, and email communications would be handled through House rules and the committee’s email system. The chair also covered decorum rules for live-streamed meetings, including professional dress, limiting food and drink at the table, and giving full attention to witnesses. Members were reminded that legislative emails are subject to public records laws and that the committee may soon transition to a new email domain. The chair also explained logistics such as bill folders, committee room storage, and emergency procedures for evacuation or shelter-in-place. No bills were debated or voted on in this meeting, but the chair noted that the committee already had roughly two dozen bills pending, including animal welfare, landfill, policy, and cat-and-dog related measures. Members were told to expect a broad mix of topics beyond agriculture, including solid waste and animal-related legislation.

Transcript Highlights:

• He mentioned that the FDA has AI data centers. That is a federal issue.
• The federal—he mentioned that, like the FDA has AI data centers. That is a federal issue.

Summary: The Arkansas Boys State House convened with a quorum, heard opening remarks from legislative leaders and guests, and then considered a series of bills focused on rural services, education, taxes, and zoning. House Bill 1001 would have increased rural health care funding through a 10% tax on individuals earning at least $300,000; supporters argued it would improve access and quality in rural areas, while opponents raised concerns about fairness, long-term funding, and whether it would drive away doctors and taxpayers. The bill failed by a vote of 24 yeas, 51 nays, and 1 present. House Bill 1002 would have limited the number of subjects rural teachers could be assigned and offered sign-on bonuses to recruit more teachers; supporters said it would reduce burnout and improve specialization, while opponents questioned funding and whether it would worsen inequities. After immediate consideration, it passed narrowly, 38 yeas, 36 nays, and 2 present. The House then debated House Bill 1003, which would regulate AI data centers through county zoning authority and a 10% tax on corporations to fund conservation efforts. Supporters said counties should be able to decide whether data centers fit local needs, while opponents warned about lost jobs, higher costs, and federal-state jurisdiction issues. The bill passed 62 yeas, 7 nays, and 3 present. House Bill 1004 would have reduced motor vehicle registration fees to offset high fuel costs, but critics argued it would reduce highway and road funding and strain the state budget; it failed 20 yeas, 46 nays, and 4 present. The chamber then took up Senate bills. Senate Bill 1 proposed incentives tied to SNAP benefits to encourage healthier food purchases and address food insecurity and obesity; supporters framed it as a way to improve access to healthy food, while opponents objected to taxing junk food and burdening SNAP users. It passed 43 yeas and 27 nays. Senate Bill 2 would require reading tests in middle school and state tutoring for students who fail; supporters said it would address literacy problems early, while opponents wanted clearer provisions for older students and implementation. It passed 67 yeas, 6 nays, and 1 present. Senate Bill 3 would cut individual and corporate income taxes to promote economic growth and ease cost-of-living pressures; supporters cited prior tax cuts and business attraction, while opponents said the benefits would mostly go to wealthy corporations and CEOs. It passed 53 yeas, 15 nays, and 16 present. Senate Bill 4 created a mixed-use zoning grant program funded by a 1% hotel tourism tax to encourage affordable housing and downtown redevelopment; it passed 51 yeas, 7 nays, and 13 present. The session ended with a motion to adjourn, which carried.

Transcript Highlights:

• He mentioned that the FDA has AI data centers. That is a federal issue. That is a federal issue.
• The federal—he mentioned that, like, the FDA has AI data centers. That is a federal issue.

Keywords: 1204, all

Summary: The meeting was an Arkansas Boy State House session that began with welcoming remarks, introductions of legislators and guests, a quorum call, prayer, and the Pledge of Allegiance. The chamber then considered several bills, with members using questions, pro and con speeches, and repeated motions for immediate consideration to end debate. The first House bill, on increasing funding for rural health care through a 10% tax on individuals earning at least $300,000, drew concerns about fairness, long-term funding, and whether it would improve quality of care; it failed 24-51. House Bill 1002, which would fund more teachers for rural schools and limit how many subjects they teach, also drew debate over funding sources and teacher burnout; it failed 38-36. House Bill 1003, creating the Arkansas Act of 26 to regulate AI data centers through local zoning and a 10% tax for conservation, passed after debate over local control, jobs, and federal versus state authority. House Bill 1004, which would reduce vehicle registration fees and shift transportation funding, failed 20-46 amid concerns about road funding and budget impacts. The chamber then moved to Senate bills. Senate Bill 1, aimed at fighting food insecurity by incentivizing healthier SNAP purchases through a Double Bucks-style program, passed 43-27. Senate Bill 2, requiring reading tests in earlier middle school grades and state tutoring for students who fail, passed overwhelmingly 67-6. Senate Bill 3, reducing the individual and corporate income tax rate from 3.7% to 3% to address cost of living and attract business, passed 53-15. Senate Bill 4, creating a mixed-use zoning grant program funded by a 1% hotel tourism tax to support affordable housing and downtown development, passed 51-7. The session ended with a motion to adjourn, which was adopted.

Transcript Highlights:

• I have one constituent in Conway, and the farmer there called Healthy Flavors, and they've got an FDA
• I've got an FDA grant where they're working with seven schools here in Arkansas right now, just getting

Summary: The committee heard extensive public testimony from youth advocates and public health speakers urging action on vaping. Witnesses said flavored products and social media are driving youth use in Arkansas, described nicotine addiction and health harms, and asked lawmakers to prohibit vaping in public indoor spaces, align vape rules with smoke-free laws, and expand prevention efforts. Committee members thanked the speakers and encouraged them to continue building support for future legislation. The main presentation was an overview of Arkansas’s Rural Health Transformation Program, a five-year federal initiative funded through CMS. State officials said Arkansas received about $209 million for the first year and may receive roughly $1 billion over five years if performance is strong. They emphasized that the program is intended for targeted, locally driven transformation rather than general operating support, debt relief, or new construction, and outlined four initiatives: Heart, PACT, Rise, and Thrive, focused on prevention, access and coordination, workforce development, and technology. Officials said applications would open in the spring, with a reimbursement-based process and a goal of launching all four initiatives by June. Members asked detailed questions about eligibility, rural definitions, school gardens, faith-based and nonprofit partnerships, mobile clinics, EMS, behavioral health, residency slots, and whether urban providers serving rural patients could apply. Officials said the program would favor regional collaboration, could support targeted renovations and expansion of existing programs, and would allow residency growth and some equipment or infrastructure purchases, but not food purchases or permanent new construction. They also said a committee of state health and finance officials would review applications, with heavy technical assistance and an expectation of quick turnaround. The committee also reviewed two DHS/Health Department rules. One implemented Medicaid and CHIP coverage and care coordination for eligible incarcerated youth before and after release, including targeted case management and screening services, with no public comments received. The other updated audiology licensing rules to reflect recent acts expanding scope of practice and changing the renewal deadline. Both rules were reviewed without objection, and the committee adjourned.